Skip to content

Investors / Remuneration Committee Charter


The Remuneration Committee of Amarin's Board of Directors is appointed by the Board of Directors to assist the board in the discharge of its responsibilities relating to (i) remuneration of the Company's executive officers, (ii) administration of the Company's equity-based plans, and (iii) such other matters relating to remuneration of executive officers and employee benefit plans of the Company as shall be delegated from time to time by the Board of Directors.

The composition of the Remuneration Committee is as follows:

Dr. James Healy (Chair)
Jan van Heek
David Stack

This page was last updated on July 8, 2013.


Committee Members

David Stack
Non-Executive Director

David Stack joined Amarin as a Non-Executive Director in December 2012. Mr. Stack is currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr. Stack has been a managing director of MPM Capital since 2005 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories from 1981 until 1993, in various positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., PepTx, Inc. and Medivo, Inc. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. We believe Mr. Stack's qualifications to sit on our board of directors include his extensive experience with pharmaceutical companies, his financial expertise and his years of experience providing strategic and financial advisory services to pharmaceutical and biotechnology organizations.

Jan van Heek
Non-Executive Director

Jan van Heek joined Amarin as a Non-Executive Director in February 2010. He has more than 30 years in the healthcare industry. He is currently a Principal and Partner at BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint, Mr. van Heek spent more than 18 years at Genzyme Corporation, most recently as Senior Advisor to the CEO and senior management team. Mr. van Heek joined Genzyme in 1991, where as Executive Vice President, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses. Mr. van Heek is currently a board member of PanGenetics BV in the Netherlands and was a board member of and Chairman of the Audit Committee of ViaCell Corporation, a US public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. Between 2007 and 2009, he was Chairman of the Board of BioVex Inc. in Woburn, MA and where he also chaired its Audit and Compensation Committees. Mr. van Heek also served on the board of Zelos Therapeutics, Inc. between 2004 and 2008. Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the US. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.